Foster, Rachel H.; Goa, Karen L. - In: PharmacoEconomics 14 (1998) 1, pp. 97-133
The availability of new atypical antipsychotics, such as risperidone, that have higher acquisition costs than conventional treatments has prompted pharmacoeconomic evaluation of their costs and benefits. Risperidone is reported to have superior efficacy to haloperidol and similar efficacy to...